ArticleJournal of neurology2021
Intravenous immunoglobulin response in new-onset refractory status epilepticus (NORSE) COVID-19 adult patients.
Article in Journal of neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Autoimmune encephalitis associated with COVID-19: A systematic review.Multiple sclerosis and related disorders · 2022Pooled it
- Unraveling the enigma of new-onset refractory status epilepticus: a systematic review of aetiologies.European journal of neurology · 2022Pooled it
- Ketamine in super-refractory status epilepticus: Combined value of inflammatory biomarkers and EEG features.Epilepsia · 2026Observational
- Cerebral hypoperfusion in post-COVID-19 cognitively impaired subjects revealed by arterial spin labeling MRI.Scientific reports · 2023Article
- Efficacy of intravenous immunoglobulin (IVIg) on COVID-19-related neurological disorders over the last 2 years: an up-to-date narrative review.Frontiers in neuroscience · 2023Review
- AI-CoV Study: Autoimmune Encephalitis Associated With COVID-19 and Its Vaccines-A Systematic Review.Journal of clinical neurology (Seoul, Korea) · 2022Article
- New-onset refractory status epilepticus as an early manifestation of multisystem inflammatory syndrome in adults after COVID-19.Epilepsia · 2022Article
- Autoimmune Encephalitis in COVID-19 Infection: Our Experience and Systematic Review of the Literature.Biomedicines · 2022Review
- New-onset status epilepticus in SARS-CoV-2 infection: a case series.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Article
- New-Onset Refractory Status Epilepticus Secondary to COVID-19 Infection in Adults: A Systematic Review.Neuropsychiatric disease and treatment · 2022Review
- Autoimmune Encephalitis After SARS-CoV-2 Infection: Case Frequency, Findings, and Outcomes.Neurology · 2021Article
- Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021Review
- Neuropsychiatric manifestations of COVID-19, potential neurotropic mechanisms, and therapeutic interventions.Translational psychiatry · 2021Review
- Epilepsy as a Comorbidity in Polymyositis and Dermatomyositis-A Cross-Sectional Study.International journal of environmental research and public health · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurological manifestations may be common in COVID-19 patients. They may include several syndromes, such as a suggested autoimmune abnormal response, which may result in encephalitis and new-onset refractory status epilepticus (NORSE). Quickly recognizing such cases and starting the most appropriate therapy is mandatory due to the related rapid worsening and bad outcomes. This case series describes two adult patients admitted to the university hospital and positive to novel coronavirus 2019 (SARS-CoV-2) infection who developed drug-resistant status epilepticus. Both patients underwent early electroencephalography (EEG) assessment, which showed a pathological EEG pattern characterized by general slowing, rhythmic activity and continuous epileptic paroxysmal activity. A suspected autoimmune etiology, potentially triggered by SARS-CoV-2 infection, encouraged a rapid work-up for a possible autoimmune encephalitis diagnosis. Therapeutic approach included the administration of 0.4 g/kg intravenous immunoglobulin, which resulted in a complete resolution of seizures after 5 and after 10 days, respectively, without adverse effects and followed by a normalization of the EEG patterns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.